Back to Search
Start Over
Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity
- Source :
- Frontiers in Immunology, Frontiers in Immunology, 2020, 11, pp.919. ⟨10.3389/fimmu.2020.00919⟩, Frontiers in Immunology, Vol 11 (2020)
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- International audience; Donor-specific antibodies (DSAs) are the main risk factor for antibody-mediated rejection (ABMR) and graft loss but could have variable pathogenicity according to their IgG subclass composition. Luminex-based test might lack sensitivity for the detection of IgG subclasses and this test does not allow quantifying the relative abundance of each IgG subclass. We investigated the precise repartition of each DSA subclass and their role in ABMR occurrence and severity, using an innovative mass spectrometry-based method. Between 2014 and 2018, we enrolled 69 patients who developed de novo DSA (n = 29 without ABMR, and n = 40 with ABMR) in two transplant centers. All IgG subclasses were detected in every samples tested: 62.7% were IgG1, 26.6% were IgG2, 6.6% were IgG3, and 4.2% were IgG4. The IgG3 proportion was significantly higher in the ABMR+ compared to the ABMR- group (8.4% vs. 5.6%, p = 0.003). The proportion of IgG1, IgG2, and IgG4 of DSA was similar between the two groups. Higher IgG3 level was associated with higher C4d deposition, higher microvascular inflammation scores, and glomerular filtration rate decline >25%. IgG3 proportion was not correlated with DSA MFI. Multivariate analysis showed that proteinuria and high level of IgG3 DSA were the only two factors independently associated with ABMR. In conclusion, de novo DSA are always composed of the four IgG subclasses, but in different proportions. High IgG3 proportion is associated with ABMR occurrence and severity and with poorer outcome, independently of DSA MFI.
- Subjects :
- 0301 basic medicine
Gastroenterology
[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity
[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
Subclass
MESH: Kidney Transplantation
Kidney transplantation
0302 clinical medicine
MESH: Risk Factors
Immunology and Allergy
MESH: Treatment Outcome
MESH: Aged
MESH: Immunoglobulin G
Proteinuria
MESH: Middle Aged
biology
MESH: Predictive Value of Tests
[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology
[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology
Antibody mediated rejection
Antibody
medicine.symptom
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
Immunology
Renal function
MESH: Graft Rejection
03 medical and health sciences
IgG subclass
Internal medicine
MESH: Severity of Illness Index
parasitic diseases
medicine
Distribution (pharmacology)
Risk factor
[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity
MESH: Humans
Mass spectrometry
business.industry
MESH: Tandem Mass Spectrometry
MESH: Adult
medicine.disease
[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
MESH: Male
MESH: Prospective Studies
MESH: Isoantibodies
body regions
MESH: France
030104 developmental biology
Antibody-mediated rejection
biology.protein
MESH: Biomarkers
De novo DSA
business
lcsh:RC581-607
MESH: Female
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 16643224
- Database :
- OpenAIRE
- Journal :
- Frontiers in Immunology, Frontiers in Immunology, 2020, 11, pp.919. ⟨10.3389/fimmu.2020.00919⟩, Frontiers in Immunology, Vol 11 (2020)
- Accession number :
- edsair.doi.dedup.....a462ddd2d2676c1ae94bc2a30b3d3e5a
- Full Text :
- https://doi.org/10.3389/fimmu.2020.00919⟩